KYORIN, Flutiform Will Make its Japanese Debut Soon - A Game Changer...
It will be the third LABA + ICS entering Japanese market for the treatment of Asthma.
Orion receives first marketing authorisations for Bufomix Easyhaler product
ORION CORPORATION STOCK EXCHANGE RELEASE 14 APRIL 2014 at 9:30 PM EEST Orion receives first marketing authorisations for Bufomix Easyhaler product Orion Corporation has received Irish and Hungarian marketing authorisation for Bufomix Easyhaler , an inhaled budesonide-formoterol combination product indicated for asthma and chronic obstructive ... (more)
The Financial Mirror
Forest Laboratories and Almirall Provide ...
NEW YORK & BARCELONA, Spain-- -- Forest Laboratories, Inc. and Almirall, S.A. today announced that they have recently received feedback from the U.S. Food and Drug Administration regarding the fixed dose combination of aclidinium and formoterol.
Long-acting inhaled therapy (beta-agonists, anticholinergics and...
Pharmacological therapy for chronic obstructive pulmonary disease is aimed at relieving symptoms, improving quality of life and preventing or treating exacerbations.Treatment tends to begin with one inhaler, and additional therapies are introduced as necessary.